Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Fried

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
Hepatology (Baltimore, Md.)|May 16, 2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET studyVarun Saxena, Vandana Khungar, Elizabeth C Verna, et al.
Gastroenterology|November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trialStefan Zeuzem, Thomas Berg, Edward Gane, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Hepatology (Baltimore, Md.)|September 16, 2020
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral TherapyAnna S Lok, Robert Perrillo, Christina M Lalama, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 7, 2018
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and CirrhosisJoseph K Lim, Ann Marie Liapakis, Mitchell L Shiffman, et al.
Hepatology Communications|November 6, 2023
Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative studyAndrew M Moon, Sarah Cook, Rachel M Swier, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failureFred Poordad, Stanislas Pol, Armen Asatryan, et al.
Gastroenterology|August 12, 2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir TherapyAnna S Lok, Mark S Sulkowski, Jens J Kort, et al.
Hepatology (Baltimore, Md.)|December 4, 2024
Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study designM Alan Brookhart, Tracy J Mayne, Charles Coombs, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 11, 2014
Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotypeMarc G Ghany, Robert Perrillo, Ruosha Li, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
Hepatology (Baltimore, Md.)|May 16, 2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET studyVarun Saxena, Vandana Khungar, Elizabeth C Verna, et al.
Gastroenterology|November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trialStefan Zeuzem, Thomas Berg, Edward Gane, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Hepatology (Baltimore, Md.)|September 16, 2020
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral TherapyAnna S Lok, Robert Perrillo, Christina M Lalama, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 7, 2018
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and CirrhosisJoseph K Lim, Ann Marie Liapakis, Mitchell L Shiffman, et al.
Hepatology Communications|November 6, 2023
Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative studyAndrew M Moon, Sarah Cook, Rachel M Swier, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failureFred Poordad, Stanislas Pol, Armen Asatryan, et al.
Gastroenterology|August 12, 2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir TherapyAnna S Lok, Mark S Sulkowski, Jens J Kort, et al.
Hepatology (Baltimore, Md.)|December 4, 2024
Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study designM Alan Brookhart, Tracy J Mayne, Charles Coombs, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 11, 2014
Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotypeMarc G Ghany, Robert Perrillo, Ruosha Li, et al.
Pageof 17